NCT06055543

Brief Summary

This study aims to compare nutritional outcomes in terms of percentage of weight gain between a new planted-based high-energy ONS and a standard high-energy ONS with animal protein (cow's mil protein) in patients at malnutrition according to Global Leadership Initiative on Malnutrition (GLIM) criteria.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
140

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Aug 2023

Shorter than P25 for phase_4

Geographic Reach
1 country

6 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 9, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

September 14, 2023

Completed
12 days until next milestone

First Posted

Study publicly available on registry

September 26, 2023

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2024

Completed
Last Updated

September 26, 2023

Status Verified

September 1, 2023

Enrollment Period

10 months

First QC Date

September 14, 2023

Last Update Submit

September 20, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change in weight

    Change in weight percentage

    Changes between baseline and final visit (12 weeks).

  • Improvement in nutritional status

    Improvement in nutritional status according to the GLIM criteria. A change in classification category from grade 2 of malnutrition to grade 1 or not meet GLIM criteria, as well as a change from grade 1 to not meet GLIM criteria are considered an improvement.

    From the baseline to the final visit (12 weeks)

Secondary Outcomes (5)

  • Change in muscle strength

    From the baseline to final visit (12 weeks)

  • Change in calf circumference

    From baseline to final visit (12 week)

  • Percentage of compliance

    During the study follow up

  • Changes in the gastrointestinal symptom scale (GSRS)

    From the baseline to final visit (12 week)

  • ONS Satisfaction

    Final visit (12 week)

Study Arms (2)

Fortimel Energy

ACTIVE COMPARATOR

Control: high-energy ONS 1.5 Kcal/m 200ml for 90 days

Dietary Supplement: Fortimel

Fortimel PlantBased

EXPERIMENTAL

Intervention: high-energy ONS 1.5 Kcal/m 200ml for 90 days

Dietary Supplement: Fortimel

Interventions

FortimelDIETARY_SUPPLEMENT

2 bottles/day of the high energy ONS

Fortimel EnergyFortimel PlantBased

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients ≥ 18 years old
  • Malnourished patients according to GLIM criteria
  • Patients with a high energy requirement (1.5kcal/ml) requiring the intake of 2 bottles of ONS per day for at least 12 weeks
  • Patients presenting any of the following clinical situations:
  • Elderly patients requiring oral nutritional support
  • Patients with digestive pathology including but not restricted to inflammatory bowel disease, short bowel syndrome, pancreatitis, without active malabsorption and maldigestion.
  • Chronic diseases such as COPD, mild to moderate renal disease, HIV
  • Oncologic patients with Eastern Cooperative Oncology Group (ECOG) 0-1
  • Patients who have given their consent to participate
  • Patients who, in the opinion of the physician, have the capacity to answer the study questionnaires themselves or their caregivers

You may not qualify if:

  • Patients who need ONS due to surgical or acute illness\*
  • Patients with known intolerance or allergy to cow's milk, soya or peas
  • Patients with hyperthyroidism. Patients with uncontrolled hypothyroidism
  • Uncontrolled diabetic patients (HbA1c \>8%)
  • Patients requiring enteral nutrition by tube or ostomy
  • Patients with moderate and serious renal insufficiency \< 30ml/min/1,73 m2
  • Patients who have value creatinine:
  • ,70 mg/dl - 150,31umol/L Men
  • ,50 mg/dl - 132,63umol/L Women
  • Patients with levels of haemoglobin \<10 g/dl, transferrin \<150 mg /dl

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

Hospital Universitario de Basurto

Bilbao, 48013, Spain

RECRUITING

Hospital Universitario Reina Sofía

Córdoba, 14004, Spain

RECRUITING

Hospital Universitario de Gran Canaria Doctor Negrín

Las Palmas de Gran Canaria, 35010, Spain

RECRUITING

Hospital Universitario de Móstoles

Madrid, 28935, Spain

RECRUITING

Hospital Universitario Virgen del Rocío

Seville, 41013, Spain

RECRUITING

Hospital Clínico Valladolid

Valladolid, 47003, Spain

RECRUITING

Related Publications (1)

  • Iglesias Hernandez NC, Ramos Carrasco A, De Luis Roman DA, de Pablos-Velasco PL, Calanas Continente A, Rodriguez Soto MJ, Lopez-Gomez JJ, Comi-Diaz C, Garcia-Rey S, Perez-Rambla C, Garcia-Luna PP. Effect of a new plant-based high-energy oral nutritional supplement in adult malnourished patients: an open-label, randomized clinical trial. Front Nutr. 2025 Nov 20;12:1667954. doi: 10.3389/fnut.2025.1667954. eCollection 2025.

MeSH Terms

Conditions

MalnutritionNeoplasmsInflammatory Bowel DiseasesPulmonary Disease, Chronic ObstructiveAcquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

Nutrition DisordersNutritional and Metabolic DiseasesGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsHIV InfectionsBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesSlow Virus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 14, 2023

First Posted

September 26, 2023

Study Start

August 9, 2023

Primary Completion

May 31, 2024

Study Completion

May 31, 2024

Last Updated

September 26, 2023

Record last verified: 2023-09

Data Sharing

IPD Sharing
Will not share

Locations